Prostate Cancer Imaging with 18F-Fluciclovine

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmaceuticals

Background:

• 18F-Fluciclovine PET is an established imaging modality for suspected prostate cancer recurrence.
• It demonstrates high specificity for identifying extraprostatic disease, even with low PSA levels and negative conventional imaging.
• Its use has been associated with improved patient management and outcomes.

Purpose of the Study:

• To evaluate the role of 18F-Fluciclovine PET in diagnosing prostate cancer recurrence.
• To highlight its utility as an adjunct to newer imaging techniques like PSMA PET.

Main Methods:

• Utilizing 18F-Fluciclovine Positron Emission Tomography (PET) for imaging.
• Assessing diagnostic performance in patients with suspected prostate cancer recurrence.
• Comparing findings with conventional imaging and PSA levels.

Main Results:

• 18F-Fluciclovine PET is highly specific for localizing prostate cancer recurrence, including extraprostatic extension.
• Effective even in cases with low prostate-specific antigen (PSA) and negative conventional imaging results.
• Demonstrated influence on patient management decisions and potential for improved outcomes.

Conclusions:

• 18F-Fluciclovine PET is a valuable tool for evaluating suspected prostate cancer recurrence.
• It offers high specificity for detecting localized disease, complementing other diagnostic methods.
• Its role may expand as an adjunct to PSMA PET for occult recurrences or negative PSMA findings.